All that doctors need so as to treat cancer successfully is data. And the data should be about several things. According to the co-founder and CEO of Tempus, that is what is missing from today’s medical research system.
There is no shortage of patient data out there, but the medical research system is facing an acute shortage of sources that combine therapeutic data with genomic information. Mr Leftkofsky revealed this recently at the Fortune Brainstorm Healthcare in San Diego.
Lefkosfsky noted that it is easy to gather molecule data. But that is not enough as they need to have the capacity to gather adequate clinical data as well. He continued to explain that this means that other than information concerning the patient’s DNA and DRN makeup, healthcare professionals need to know the type of treatments they are on and how they are responding to the treatment.
A researcher observing breast-cancer patients taking Herceptin should, for example, consider why the drug is working on 40 percent and not 60 percent of the patients. Also, he should seek to find out if there is anything else that is taking place in the life of the patients who are not being helped. Are they on other drugs? Are they diabetic? Leftkofsky noted that this type of information should flow freely between medical researchers and all other medical professionals. Click here to know more.
About Eric Lefkofsky
When Eric Leftkofsky’s wife was diagnosed with breast cancer, he was inspired to start Tempus. As they sat in clinics, he observed that truck drivers had ways to gather better data about how to achieve their objectives at the workplace than oncologists do. He also noted that they often lacked the right data on how some treatments work in some cohort of patients. For this reason, he decided to invent a platform that people starting in oncology and those working on neurological disorders can use to collect data for analysis.
Lefkofsky is also the co-founder of Groupon (NASDAQ: GRPN), an international e-commerce marketplace, and Lightbank, a venture fund that invests mainly in disruptive technology businesses. In 2006, Lefkofsky also established the Lefkofsky Family Foundation to advance high-impact initiatives that make life better in the communities served.
Everyone should be aware that perhaps one of the things that keeps humanity functioning with the efficiency that it does today should be credited largely to advancements that have occurred in the field of science. Science has enabled us as a society to advance greatly towards newer and quite exciting beginnings in which we are introduced to an era in which we can expect much greater advancements to occur, some of which we may be approaching in the very beginning stages.
Oncotarget is a website that regularly keeps up with science and all of its latest news and advancements. If you’re unsure about what you can do to make certain improvements in your learning in the field of science, it’s highly recommended for you to contact one of the representatives who are available to assist at Oncotarget. It is a website that has been created with a minimalist design to let users know that one of the things that the website is going to be known for is science and studies, not a place where those who have no intention of learning or contributing can navigate to and chat away for leisurely pleasure. Oncotarget is also available on Dove Press. Although that may sound a bit cruel to an extent, any true enthusiast of the scientific field is well aware of there hardly being any time for extra fun when there is so much to learn and so much room for advancements/improvements for us to be a part of. Plus, learning about science, its discoveries, advancements, and potential outlook should be considered as being fun itself as such instances are certainly exciting to know and learn about. Be sure to visit the page regularly so that you can get ideas on how to implement science into your life on a daily basis. It is truly remarkable what science means to the world. Follow Oncotarget on Twitter.
Cancer is one of those illnesses that has been around for many years and it has affected the lives of many people either directly or indirectly. There have been many advancements throughout the years, but none were able to make a huge impact until now. Have you ever heard of a guy named Clay Siegall? Seattle Genetics is one of the leading biotech organizations that specialize in the development and commercialization of cancer breakthrough therapies. Clay Siegall is the current CEO and President of this exclusive organization and this duo is revolutionizing cancer research through innovation.
Clay Siegall is a well-respected individual in this industry and he one of the most impressive resume’s to back it up. This guy has a Ph.D in Genetics from George Washington University as well as a (BS) in Zoology from the University of Maryland. He’s thought of as a “man of man acts” also thanks to having such a broad educational background in a variety of subjects. Siegal’s huge heart has allowed him to help and save many lives throughout his professional career as he’s worked with many high profile organizations such as The National Cancer Institute, Bristol Myers Squibb, and The National Institute of Health. Seattle Genetics has grown into a powerhouse that hosts over 800 employees. Antibody Drug Conjugates are some of the best cancer fighting medications and this organization produces the best. Dr. Siegal has entered the advanced medications into multiple strategic deals with GlaxoSmithKline, Pfizer, and Genentech. Having these deals allow the powerful medications to be used in other countries. As of today, Seattle Genetics’ (ADCs) have brought in over $325 Million in sales.
Thanks to the organization’s solid reputation and remarkable products, Seattle Genetics was ranked on the Forbes list as one of the fastest growing companies in the U.S. Dr. Clay Siegall’s vision is finally coming true and the number of lives he has saved is a true testament to his success.